Cytosorbents Statistics
Total Valuation
Cytosorbents has a market cap or net worth of $38.25 million. The enterprise value is $59.93 million.
Important Dates
The next estimated earnings date is Wednesday, May 13, 2026, after market close.
| Earnings Date | May 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Cytosorbents has 62.70 million shares outstanding. The number of shares has increased by 14.32% in one year.
| Current Share Class | 62.70M |
| Shares Outstanding | 62.70M |
| Shares Change (YoY) | +14.32% |
| Shares Change (QoQ) | +0.08% |
| Owned by Insiders (%) | 12.57% |
| Owned by Institutions (%) | 26.95% |
| Float | 54.82M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.00 |
| Forward PS | n/a |
| PB Ratio | 6.29 |
| P/TBV Ratio | 13.85 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.62 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.13, with a Debt / Equity ratio of 4.93.
| Current Ratio | 2.13 |
| Quick Ratio | 1.42 |
| Debt / Equity | 4.93 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.45 |
Financial Efficiency
Return on equity (ROE) is -96.39% and return on invested capital (ROIC) is -24.38%.
| Return on Equity (ROE) | -96.39% |
| Return on Assets (ROA) | -19.44% |
| Return on Invested Capital (ROIC) | -24.38% |
| Return on Capital Employed (ROCE) | -41.30% |
| Weighted Average Cost of Capital (WACC) | 10.05% |
| Revenue Per Employee | $287,310 |
| Profits Per Employee | -$63,550 |
| Employee Count | 129 |
| Asset Turnover | 0.81 |
| Inventory Turnover | 2.64 |
Taxes
| Income Tax | -401,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -40.59% in the last 52 weeks. The beta is 1.48, so Cytosorbents's price volatility has been higher than the market average.
| Beta (5Y) | 1.48 |
| 52-Week Price Change | -40.59% |
| 50-Day Moving Average | 0.66 |
| 200-Day Moving Average | 0.80 |
| Relative Strength Index (RSI) | 44.05 |
| Average Volume (20 Days) | 110,422 |
Short Selling Information
The latest short interest is 2.02 million, so 3.22% of the outstanding shares have been sold short.
| Short Interest | 2.02M |
| Short Previous Month | 2.02M |
| Short % of Shares Out | 3.22% |
| Short % of Float | 3.69% |
| Short Ratio (days to cover) | 30.16 |
Income Statement
In the last 12 months, Cytosorbents had revenue of $37.06 million and -$8.20 million in losses. Loss per share was -$0.13.
| Revenue | 37.06M |
| Gross Profit | 26.49M |
| Operating Income | -14.24M |
| Pretax Income | -8.60M |
| Net Income | -8.20M |
| EBITDA | -12.74M |
| EBIT | -14.24M |
| Loss Per Share | -$0.13 |
Full Income StatementBalance Sheet
The company has $6.25 million in cash and $29.11 million in debt, with a net cash position of -$22.86 million or -$0.36 per share.
| Cash & Cash Equivalents | 6.25M |
| Total Debt | 29.11M |
| Net Cash | -22.86M |
| Net Cash Per Share | -$0.36 |
| Equity (Book Value) | 5.90M |
| Book Value Per Share | 0.09 |
| Working Capital | 10.93M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$12.38 million and capital expenditures -$164,000, giving a free cash flow of -$12.54 million.
| Operating Cash Flow | -12.38M |
| Capital Expenditures | -164,000 |
| Depreciation & Amortization | 1.50M |
| Net Borrowing | 2.48M |
| Free Cash Flow | -12.54M |
| FCF Per Share | -$0.20 |
Full Cash Flow StatementMargins
Gross margin is 71.48%, with operating and profit margins of -38.42% and -22.12%.
| Gross Margin | 71.48% |
| Operating Margin | -38.42% |
| Pretax Margin | -23.20% |
| Profit Margin | -22.12% |
| EBITDA Margin | -34.38% |
| EBIT Margin | -38.42% |
| FCF Margin | n/a |
Dividends & Yields
Cytosorbents does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.32% |
| Shareholder Yield | -14.32% |
| Earnings Yield | -22.12% |
| FCF Yield | -33.83% |
Analyst Forecast
The average price target for Cytosorbents is $5.38, which is 781.82% higher than the current price. The consensus rating is "Buy".
| Price Target | $5.38 |
| Price Target Difference | 781.82% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 49.57% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 5, 2014. It was a reverse split with a ratio of 1:25.
| Last Split Date | Dec 5, 2014 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
Cytosorbents has an Altman Z-Score of -8.92 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.92 |
| Piotroski F-Score | 2 |
